MAM
PromaxBDA announces speakers for its 12th edition
MUMBAI: PromaxBDA, the association that represents more than 10,000 companies and promotion and marketing professionals at every major media organisation in broadcast media, has announced the 12th edition of its annual conference, PromaxBDA India 2015.
This year’s conference will witness participation of prominent visionaries discussing topics that contribute to the growth of digital and advertising space. Some of the key speakers and trainers include David Shing – Digital Prophet – AOL, Nicole Velik – Director/Founder – Ideas Bodega, Linda Button – Brand Personality Expert – Tooth+Nail, Rob Middleton – VP, Network Presentation Content Group – ASTRO, Liz Dunning – Co-founder – Dunning Penney Jones, Amanda Herbert – Marketing & Communications Director – Discovery Networks Asia Pacific and Glenn Urquhart – Group Creative Director – The LifeStyle Channel, Foxtel Networks Australia.
This year PromaxBDA India has introduced a brand new conference format, where they will be holding PromaxBDA Boot Camps and PromaxBDA Masterclass Conference. The inaugural PromaxBDA Boot Camps will bring in the latest creative techniques in promotion-creation while the Masterclass Conference is tailored to create a local and global overlook for senior-level producers, executives, leaders and decision makers. The Masterclass Conference will be opened with a keynote address by the renowned David Shing – Digital Prophet – AOL.
Along with this, PromaxBDA India has also introduced two new categories in its current bouquet of 41 award categories. The new categories are BEST DRAMA PROMO NOT IN HINDI OR ENGLISH and BEST ENTERTAINMENT PROMO NOT IN HINDI OR ENGLISH in the Regional Categories 2015.
Commenting on this year’s conference and the new additions, Rajika Mittra, Country Head (India), PromaxBDA said, “We are glad to announce the 12th PromaxBDA India Conference 2015. With media and entertainment industry evolving at an enormous speed and digital space dominating as a medium, this year we have introduced a fresher format, which aims at emphasizing on the importance of the digital medium. We have received encouraging response to the earlier summits and I am sure that this year too we will have an exciting time with everyone.”
Invited this year again to grace the PromaxBDA India 2015’s Conference Chair position is Raj Nayak, CEO, Colors. He shared, “For colleagues who have attended the previous editions of the PromaxBDA India Conference, we look forward to having you back with us. Get ready to be inspired by the unexpected and the eye-opening. Those new to this conference will find that the television industry goes beyond traditionally set boundaries. The future of television is speeding ahead and a multi-discipline outfit might be the way forward.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
